University of Wisconsin-Madison gene medicine developer Design Therapeutics has attracted SR One for its series A round.

Design Therapeutics, a US-based degenerative disorder medication developer spun out by University of Wisconsin-Madison, closed a $45m series A round on Friday led by SR One, the corporate venturing fund of pharmaceutical firm GlaxoSmithKline.
Hedge fund manager Cormorant Asset Management, venture capital firm Quan Capital and investment group WestRiver also took part in the series A round.
Design Therapeutics is targeting degenerative diseases caused by malignant recurrences of genetic code, known as nucleotide repeat disorders, which, depending on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?